Correlation Between Bolt Biotherapeutics and Cingulate

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bolt Biotherapeutics and Cingulate at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bolt Biotherapeutics and Cingulate into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bolt Biotherapeutics and Cingulate, you can compare the effects of market volatilities on Bolt Biotherapeutics and Cingulate and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bolt Biotherapeutics with a short position of Cingulate. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bolt Biotherapeutics and Cingulate.

Diversification Opportunities for Bolt Biotherapeutics and Cingulate

0.46
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Bolt and Cingulate is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Bolt Biotherapeutics and Cingulate in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cingulate and Bolt Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bolt Biotherapeutics are associated (or correlated) with Cingulate. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cingulate has no effect on the direction of Bolt Biotherapeutics i.e., Bolt Biotherapeutics and Cingulate go up and down completely randomly.

Pair Corralation between Bolt Biotherapeutics and Cingulate

Given the investment horizon of 90 days Bolt Biotherapeutics is expected to under-perform the Cingulate. But the stock apears to be less risky and, when comparing its historical volatility, Bolt Biotherapeutics is 5.84 times less risky than Cingulate. The stock trades about -0.05 of its potential returns per unit of risk. The Cingulate is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  9,180  in Cingulate on August 25, 2024 and sell it today you would lose (8,708) from holding Cingulate or give up 94.86% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Bolt Biotherapeutics  vs.  Cingulate

 Performance 
       Timeline  
Bolt Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bolt Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Cingulate 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cingulate has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Bolt Biotherapeutics and Cingulate Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bolt Biotherapeutics and Cingulate

The main advantage of trading using opposite Bolt Biotherapeutics and Cingulate positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bolt Biotherapeutics position performs unexpectedly, Cingulate can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cingulate will offset losses from the drop in Cingulate's long position.
The idea behind Bolt Biotherapeutics and Cingulate pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios